Bioventus Inc

For the period ended Dec 31, 2023. Filed Mar 12, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 12, 2024

BVS$11.18+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ and Members’ Equity

Members’Equity · Class A Common Stock · Class B Common Stock · Additional Paid-in Capital · Accumulated other comprehensive income (loss) · Accumulated Deficit · Non-controlling Interest · Total Stockholders' andMembers’Equity
Shares · Amount · Shares · Amount
December 31, 2020	$144,160		—		$—		—		$—			$—			$—			$—			$—			$144,160
Prior to Organizational Transactions:
Refund from members	123		—		—		—		—			—			—			—			—			123
Equity-based compensation	(39)		—		—		—		—			—			—			—			—			(39)
Net income	25,977		—		—		—		—			—			—			—			—			25,977
Other comprehensive loss	(1,507)		—		—		—		—			—			—			—			—			(1,507)
Effect of Organizational Transactions	(168,714)		31,838,589		32		15,786,737		16			41,813			—			—			79,119			(47,734)
Subsequent to Organizational Transactions:
Initial public offering, net of offering costs	—		9,200,000		9		—		—			106,441			—			—			—			106,450
Issuance of Class A common stock for equity plans	—		169,125		—		—		—			1,617			—			—			—			1,617
Issuance of Class A common stock for acquisitions, net of registration fees	—		18,340,790		18		—		—			272,706			—			—			—			272,724
Distribution to Continuing LLC Owner	—		—		—		—		—			—			—			—			(3,306)			(3,306)
Net loss	—		—		—		—		—			—			—			(6,602)			(9,789)			(16,391)
Deconsolidation of variable interest entity	—		—		—		—		—			—			—			—			3,746			3,746
Equity based compensation	—		—		—		—		—			15,059			—			—			4,825			19,884
Replacement equity awards in connection with acquisitions	—		—		—		—		—			27,636			—			—			—			27,636
Acquisition of noncontrolling interest	—		—		—		—		—			—			—			—			200			200
Change in noncontrolling interest allocations	—		—		—		—		—			8,046			—			—			65,821			73,867
Other comprehensive income	—		—		—		—		—			—			179			—			70			249
December 31, 2021	$—		59,548,504	$59		15,786,737	$16			$473,318			$179			$(6,602)			$140,686			$607,656
Issuance of Class A common stock for equity plans		2,514,510		3		—		—			5,819			—			—			—		5,822
Deferred taxes on equity rebalancing		—		—		—		—			(1,977)			—			—			—			(1,977)
Net loss		—		—		—		—			—			—			(158,704)			(54,687)			(213,391)
Tax withholdings on equity compensation awards		—		—		—		—			(3,352)			—			—			—			(3,352)
Deconsolidation of noncontrolling interest		—		—		—		—			—			—			—			247			247
Equity based compensation		—		—		—		—			14,180			—			—			3,405			17,585
Change in noncontrolling interest allocations		—		—		—		—			2,588			—			—			(2,588)			—
Other comprehensive loss		—		—		—		—			—			(289)			—			(79)			(368)
December 31, 2022		62,063,014		$62		15,786,737		$16			$490,576			$(110)			$(165,306)			$86,984			$412,222
Issuance of Class A common stock for equity plans		1,204,422		1		—		—			777			—			—			—			778
Net loss		—		—		—		—			—			—			(156,230)			(39,395)			(195,625)
Equity based compensation		—		—		—		—			2,388			—			—			334			2,722
Change in noncontrolling interest allocations		—		—		—		—			513			—			—			(513)			—
Distributions to members		—		—		—		—			—			—			—			(111)			(111)
Other comprehensive income		—		—		—		—			—			904			—			228			1,132
December 31, 2023		63,267,436		$63		15,786,737		$16			$494,254			$794			$(321,536)			$47,527			$221,118

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.